U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H28N4O6S2
Molecular Weight 472.579
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFATHIAMIDINE

SMILES

[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC(NC(C)C)=NC(C)C)C(O)=O

InChI

InChIKey=JYXACOFERDBGGQ-RHSMWYFYSA-N
InChI=1S/C19H28N4O6S2/c1-9(2)20-19(21-10(3)4)31-8-13(25)22-14-16(26)23-15(18(27)28)12(6-29-11(5)24)7-30-17(14)23/h9-10,14,17H,6-8H2,1-5H3,(H,20,21)(H,22,25)(H,27,28)/t14-,17-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14761333 | https://www.ncbi.nlm.nih.gov/pubmed/3104591 | https://www.ncbi.nlm.nih.gov/pubmed/25499488

Cefathiamidine is a beta-lactam antibiotic that exhibits a broad spectrum of bactericidal activity against gram-positive bacteria. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Xianlisu

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
First four failures of cefathiamidine to treat urogenital gonorrhoea in Guangzhou, China, 2014-15.
2017 Jun
Patents

Patents

Sample Use Guides

1000mg cefathiamidine intramuscularly
Route of Administration: Intramuscular
In Vitro Use Guide
S . faecalis NCTC 775, S . faecium NCTC 7171 and a highly beta-lactam-resistant clinical isolate of S . faecium, strain 37, were used. MICs were determined in Antibiotic Medium 3 (Bacto-penassay broth, Difco) by the broth dilution method. The susceptibility to each of penicillin, ciprofloxacin, spectinomycin and azithromycin was interpreted according to the World Health Organization (WHO) Western Pacific Region Program criteria (Cefathiamidine MIC=2mg/L)
Name Type Language
CEFATHIAMIDINE
WHO-DD  
Common Name English
LS-150050
Code English
(7R)-7-(2-((N,N'-DIISOPROPYLAMIDINO)THIO)ACETAMIDO)CEPHALOSPORANIC ACID
Common Name English
(6R,7R)-7-(2-((N,N'-DIISOPROPYLAMIDINO)THIO)ACETAMIDO)-3-(HYDROXYMETHYL)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID ACETATE (ESTER)
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-((ACETYLOXY)METHYL)-7-((2-((((1-METHYLETHYL)AMINO)((1-METHYLETHYL)IMINO)METHYL)THIO)ACETYL)AMINO)-8-OXO-, (6R,7R)-
Systematic Name English
XIANLISU
Brand Name English
Cefathiamidine [WHO-DD]
Common Name English
Code System Code Type Description
SMS_ID
100000127416
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
MESH
C018866
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID60954696
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
PUBCHEM
15942748
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
FDA UNII
8M7CAS5T8L
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
EVMPD
SUB33452
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
DRUG CENTRAL
5168
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY
CAS
33075-00-2
Created by admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
PRIMARY